AU8800598A - B7-binding molecules for treating immune diseases - Google Patents

B7-binding molecules for treating immune diseases

Info

Publication number: AU8800598A
Authority: AU; Australia
Prior art keywords: binding molecules; immune diseases; treating immune; treating; diseases
Prior art date: 1997-06-20
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU88005/98A

Inventor

Alfons Bosman

Marie-Ange Buyse

Katrien Lorre

Erwin Sablon

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Fujirebio Europe NV SA

Original Assignee

Innogenetics NV SA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-06-20

Filing date

1998-06-22

Publication date

1999-01-04

1998-06-22 Application filed by Innogenetics NV SA filed Critical Innogenetics NV SA

1999-01-04 Publication of AU8800598A publication Critical patent/AU8800598A/en

Status Abandoned legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Pharmacology & Pharmacy (AREA)
Mycology (AREA)
Microbiology (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Cell Biology (AREA)
Toxicology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)

AU88005/98A 1997-06-20 1998-06-22 B7-binding molecules for treating immune diseases Abandoned AU8800598A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP97870092		1997-06-20
EP97870092		1997-06-20
PCT/EP1998/003791 WO1998058965A2 (en)	1997-06-20	1998-06-22	B7-binding molecules for treating immune diseases

Publications (1)

Publication Number	Publication Date
AU8800598A true AU8800598A (en)	1999-01-04

Family

ID=8231013

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU88005/98A Abandoned AU8800598A (en)	1997-06-20	1998-06-22	B7-binding molecules for treating immune diseases

Country Status (4)

Country	Link
EP (1)	EP0988321A2 (en)
AU (1)	AU8800598A (en)
CA (1)	CA2292415A1 (en)
WO (1)	WO1998058965A2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2001068132A1 (en) *	2000-03-14	2001-09-20	Genetics Institute, Inc.	Use of a combination of agents that modulate b7 activity in inhibiting intestinal allograft rejection
WO2001068133A1 (en) *	2000-03-14	2001-09-20	Genetics Institute, Inc.	Use of rapamycin and agents that inhibit b7 activity in immunomodulation
AU2001247401A1 (en) *	2000-03-14	2001-09-24	Genetics Institute Inc.	Therapies that improve graft survival, using antibodies against a b7 antigen
MXPA02010011A (en)	2000-04-11	2003-04-25	Genentech Inc	Multivalent antibodies and uses therefor.
JP2004500863A (en)	2000-06-06	2004-01-15	ブリストル−マイヤーズ　スクイブ　カンパニー	B7-related nucleic acids and polypeptides useful for immunomodulation
US20030031675A1 (en) *	2000-06-06	2003-02-13	Mikesell Glen E.	B7-related nucleic acids and polypeptides useful for immunomodulation
US7531168B2 (en)	2001-02-16	2009-05-12	Genetics Institute Llc	Method for downmodulating immune response in type I diabetes
EP1423402A4 (en) *	2001-08-02	2006-07-05	Lilly Co Eli	Novel polypeptide analogs and fusions and their methods of use
US20060002935A1 (en)	2002-06-28	2006-01-05	Domantis Limited	Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US9321832B2 (en)	2002-06-28	2016-04-26	Domantis Limited	Ligand
AU2005250216B2 (en)	2004-06-01	2009-12-10	Domantis Limited	Bispecific fusion antibodies with enhanced serum half-life
US7563443B2 (en)	2004-09-17	2009-07-21	Domantis Limited	Monovalent anti-CD40L antibody polypeptides and compositions thereof
KR20070084069A (en)	2004-10-08	2007-08-24	도만티스 리미티드	Single domain antibody against TENF1 and method of using the same
EP1841796A2 (en)	2004-12-02	2007-10-10	Domantis Limited	Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
GB0621513D0 (en)	2006-10-30	2006-12-06	Domantis Ltd	Novel polypeptides and uses thereof
CN102159590A (en)	2008-07-18	2011-08-17	百时美施贵宝公司	CD28 binding monovalent compositions and methods of use
EA024877B1 (en)	2008-10-02	2016-10-31	Эмерджент Продакт Дивелопмент Сиэтл, Ллс	Cd86 antagonist multi-target binding proteins
WO2014120916A1 (en)	2013-02-01	2014-08-07	Bristol-Myers Squibb Company	Pegylated domain antibodies monovalent for cd28 binding and methods of use
IL254335B2 (en) *	2015-03-16	2023-04-01	Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd	Isolated peptides derived from the b7 ligand dimer interface and uses thereof
EP3371208B8 (en)	2015-11-02	2024-10-23	Five Prime Therapeutics, Inc.	Cd80 extracellular domain polypeptides and their use in cancer treatment
EP3515494A4 (en)	2016-09-26	2020-10-07	The Brigham and Women's Hospital, Inc.	B-CELL-MEDIATED IMMUNSUPPRESSION REGULATORS
EA201992586A1 (en)	2017-04-28	2020-03-03	Файв Прайм Терапьютикс, Инк.	METHODS FOR TREATING USING THE EXTRACELLULAR DOMAIN CD80 POLYPEPTIDES
CN110305220B (en) *	2018-03-27	2022-10-11	孙嘉琳	Cancer-targeted enhanced anti-tumor fusion protein and preparation method and application thereof
CN110305221B (en) *	2018-03-27	2022-10-11	孙嘉琳	Enhanced anti-tumor fusion protein, preparation method and application
JP2024537689A (en) *	2021-09-22	2024-10-16	ノーティラス・サブシディアリー・インコーポレイテッド	Methods and systems for determining polypeptide interactions - Patents.com

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5747034A (en) *	1992-07-09	1998-05-05	Chiron Corporation	Methods and materials for the induction of T cell anergy
AU4158396A (en) *	1994-11-10	1996-06-06	Dana-Farber Cancer Institute	Methods for inhibiting graft versus host disease in bone marrow transplantation
US6113898A (en) *	1995-06-07	2000-09-05	Idec Pharmaceuticals Corporation	Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
EP0922111B1 (en) *	1996-07-23	2004-12-01	Tanox Pharma B.V.	Induction of t cell tolerance using a soluble molecule that can simultaneously block two costimulatory pathways

1998
- 1998-06-22 EP EP98939523A patent/EP0988321A2/en not_active Withdrawn
- 1998-06-22 AU AU88005/98A patent/AU8800598A/en not_active Abandoned
- 1998-06-22 CA CA002292415A patent/CA2292415A1/en not_active Abandoned
- 1998-06-22 WO PCT/EP1998/003791 patent/WO1998058965A2/en not_active Ceased

Also Published As

Publication number	Publication date
WO1998058965A2 (en)	1998-12-30
WO1998058965A3 (en)	1999-05-14
EP0988321A2 (en)	2000-03-29
CA2292415A1 (en)	1998-12-30

Publication	Publication Date	Title
AU8800598A (en)	1999-01-04	B7-binding molecules for treating immune diseases
AU9403798A (en)	1999-04-12	Human regulatory molecules
AU5268696A (en)	1996-11-07	Novel compounds and methods for therapy
AU4052897A (en)	1998-03-19	Cancer treatment method
AU4780596A (en)	1996-09-23	Hemi-wheeled walker
AU3829895A (en)	1996-05-06	Methods for treating resistant tumors
AU7823098A (en)	1998-12-21	Methods for treating obesity
AU1542895A (en)	1995-08-21	Surface treatment
AU3124295A (en)	1995-12-05	Surface treatment techniques
AU1184399A (en)	1999-05-31	Therapeutic molecules
AUPO900097A0 (en)	1997-10-02	Process
AU7166896A (en)	1997-04-01	Cancer treatment
AU8068198A (en)	1998-12-30	Methods for treating human cancers
AU9551498A (en)	1999-05-17	Process
AU1979499A (en)	1999-07-12	Apparatus for therapeutic electromagnetic treatment
AU2547895A (en)	1995-12-05	Therapeutic phenoxyalkylheterocycles
AUPM885894A0 (en)	1994-11-10	Therapeutic molecules
AU4582597A (en)	1998-05-11	Therapeutic proteins
AU5597696A (en)	1997-01-02	Treatment system
AU4703699A (en)	2000-01-17	Immune system molecules
AU9198898A (en)	1999-04-05	Methods for treating ocular diseases
AU3645795A (en)	1996-05-06	Therapeutic molecules
AUPO926397A0 (en)	1997-10-09	Novel therapeutic molecules
AU6078396A (en)	1997-01-30	Surface treatment
AU4104997A (en)	1998-04-02	Therapeutic molecules

Legal Events

Date	Code	Title	Description
2000-03-02	MK6	Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase